histone acetylation modifiers in the pathogenesis of alzheimer’s disease
Clicks: 179
ID: 251136
2015
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
30.0
/100
178 views
15 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
It is becoming more evident that histone acetylation, as one of the epigenetic modifications or markers, plays a key role in the etiology of Alzheimer’s disease (AD). Histone acetylases (HATs) and histone deacetylases (HDACs) are the well-known covalent enzymes that modify the reversible acetylation of lysine residues in histone amino-terminal domains. In AD, however, the roles of these enzymes are controversial. Some recent studies indicate that HDAChistone deacetylases inhibitors are neuroprotective by regulating memory and synaptic dysfunctions deficit in cellular and animal models of AD, while on the other hand, increases in histone acetylation have been implicated in AD pathology. In this review, we focus on the recent advances on the roles of histone acetylation covalent enzymes in AD and discuss how targeting these enzymes can ultimately lead to therapeutic approaches for treating AD.
| Reference Key |
elu2015frontiershistone
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Xi eLu;Li eWang;Caijia eYu;Daohai eYu;Gang eYu |
| Journal | macromolecular bioscience |
| Year | 2015 |
| DOI |
10.3389/fncel.2015.00226
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.